Quantcast

Intra-arterial tissue plasminogen activator and abciximab in patients with acute basilar artery occlusion.

Research paper by A A Chiti, G G Gialdini, E E Terni, N N Giannini, M M Gennaro, G A GA Lazzarotti, M M Puglioli, G G Orlandi, U U Bonuccelli

Indexed on: 25 May '13Published on: 25 May '13Published in: Neurological Sciences



Abstract

Acute basilar artery occlusion has a poor prognosis and best treatment has not been assessed yet; as for intra-arterial treatment, no "gold standard" exists. We evaluated a series of ten patients treated with intra-arterial combination of recombinant tissue plasminogen activator (rtPA) and abciximab. Partial/complete recanalisation was achieved in all patients and good outcome (1 month Modified Rankin Scale 0-2) in eight cases, while one patient had symptomatic intracranial haemorrhage and died. Such outcome appears significantly better if compared with the results of Basilar Artery International Cooperation Study, suggesting that intra-arterial administration of rtPA and abciximab may be a promising option in patients with acute basilar artery occlusion undergoing endovascular treatment.